STRYKER REPORTS THIRD QUARTER 2026 OPERATING RESULTS

STRYKER CORP (SYK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STRYKER REPORTS THIRD QUARTER 2026 OPERATING RESULTS Portage, Michigan - October 29, 2026 - Stryker (NYSE:SYK) reported operating results for the third quarter of 2026: Third Quarter Results • Reported net sales increased 7.7% to $6.5 billion • Organic net sales incr

Event · Earnings
Also in this documentBuyback · $3BGuidance · 6.5%–7%

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SYKNeutralHigh
01

Why it matters

the updated guidance suggests slower organic growth and lower EPS, likely leading to a near‑term price dip, while the strong unit‑volume growth and share‑repurchase program provide some support.

02

Market read

Stryker's earnings and guidance revision are the primary market-moving event; sector peers may be indirectly affected.

03

What to watch

foreign currency and pricing impacts were noted as modestly positive, which could offset some of the guidance downside

Relevance 8/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readSYK · third quarter of 2026 · ended September 30, 2026

Stryker reported third-quarter net sales growth of 7.7% to $6.5 billion, while adjusted EPS increased 10.3% to $3.52 and reported EPS decreased 11.7% to $1.96.

→Mixed quarter

Sales and adjusted earnings grew at double-digit and high-single-digit rates, respectively, but management said performance fell short of its expectations and reported operating income, net earnings and diluted EPS declined amid goodwill and other impairments and special charges.

Revenue
$6.52B
7.7 % y/y
MedSurg and Neurotechnology
$3.66B
9.2 % y/y
EPS · non-GAAP
$ 3.52
10.3 % y/y
full year 2026 outlook
organic net sales growth in the range of 6.5% to 7.0%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three monthsGAAP$6.52B–7.7 %
Cost of sales, three monthsGAAP$2.27B–3.0 %
Gross profit, three monthsGAAP$4.25B–10.3 %
Gross profit margin, three monthsGAAP65.2 %––
Research, development and engineering expenses, three monthsGAAP$433M–5.6 %
Selling, general and administrative expenses, three monthsGAAP$2.31B–13.1 %
Amortization of intangible assets, three monthsGAAP$175M–(7.4) %
Goodwill and other impairments, three monthsGAAP$293M–nm
Total operating expenses, three monthsGAAP$3.21B–18.3 %
Operating income, three monthsGAAP$1.03B–(8.9) %
Operating income margin, three monthsGAAP15.9 %––
Other income (expense), net, three monthsGAAP−$37M–(65.1) %
Earnings before income taxes, three monthsGAAP$997M–(3.1) %
Income taxes, three monthsGAAP$244M–43.5 %
Net earnings, three monthsGAAP$753M–(12.3) %
Basic EPS, three monthsGAAP$ 1.97–(12.4) %
Diluted EPS, three monthsGAAP$ 1.96–(11.7) %
Adjusted gross profit, three monthsnon-GAAP$4.27B––
Adjusted gross profit margin, three monthsnon-GAAP65.4 %––
Adjusted operating income, three monthsnon-GAAP$1.71B––
Adjusted operating income margin, three monthsnon-GAAP26.2 %–increased 60 bps
Adjusted net earnings, three monthsnon-GAAP$1.36B–10.1 %
Adjusted diluted EPS, three monthsnon-GAAP$ 3.52–10.3 %
Net sales, nine monthsGAAP$19.13B–6.6 %
Gross profit, nine monthsGAAP$12.56B–9.8 %
Gross profit margin, nine monthsGAAP65.6 %––
Operating income, nine monthsGAAP$3.63B–17.6 %
Operating income margin, nine monthsGAAP19.0 %––
Net earnings, nine monthsGAAP$2.77B–15.7 %
Diluted EPS, nine monthsGAAP$ 7.19–16.0 %
Adjusted operating income, nine monthsnon-GAAP$4.78B––
Adjusted operating income margin, nine monthsnon-GAAP25.0 %––
Adjusted net earnings, nine monthsnon-GAAP$3.79B––
Adjusted diluted EPS, nine monthsnon-GAAP$ 9.81––
Net cash provided by operating activities, nine monthsGAAP$3.30B––
Purchases of property, plant and equipment, nine monthsGAAP−$605M––

Segments

SegmentRevenueq/qy/y
MedSurg and NeurotechnologyOrganic net sales increased 9.1% primarily driven by increased unit volume.$3.66B–9.2 %
OrthopaedicsOrganic net sales increased 5.9% from increased unit volume.$2.86B–5.7 %
InstrumentsNot stated.$996M–5.1 %
EndoscopyNot stated.$1.02B–13.9 %
MedicalNot stated.$1.08B–9.7 %
VascularNot stated.$566M–8.0 %
KneesNot stated.$635M–1.1 %
HipsNot stated.$453M–(1.0) %
Trauma and ExtremitiesNot stated.$1.01B–5.3 %
Ortho TechNot stated.$754M–15.8 %
Spinal ImplantsNot stated.$4M–(43.9) %
United StatesNot stated.$4.95B–8.3 %
InternationalNot stated.$1.57B–5.7 %

full year 2026 outlook

  • Revenueorganic net sales growth in the range of 6.5% to 7.0%
  • Noteadjusted net earnings per diluted share to be in the range of $14.80 to $14.90
  • NoteSales guidance includes a modestly positive pricing impact.
  • NoteForeign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share should rates hold near current levels.

Capital returns

  • We repurchased $1.0 billion of our common stock in the third quarter of 2026.
  • Payments of dividends were $ (1,012) million for the nine months 2026.
  • Repurchases of common stock were $ (1,000) million for the nine months 2026.
  • In October 2026 our Board of Directors approved an increase of $3.0 billion to our existing share repurchase program.

What drove it

  • Consolidated organic net sales increased 7.7% primarily driven by increased unit volume.
  • MedSurg and Neurotechnology organic net sales increased 9.1% primarily driven by increased unit volume.
  • Orthopaedics organic net sales increased 5.9% from increased unit volume.
  • Adjusted operating income margin increased 60 bps to 26.2%.

Concerns

  • Management stated that the quarter's good overall performance fell short of its expectations.
  • Reported operating income decreased 8.9% to $ 1,034 million and reported operating income margin was 15.9%, compared with 18.7%.
  • Goodwill and other impairments were $ 293 million, compared with $ 73 million.
  • Reported net earnings decreased 12.3% to $ 753 million and reported diluted EPS decreased 11.7% to $ 1.96.
  • Hips sales declined (1.0) % and Spinal Implants sales declined (43.9) %.

What to watch

  • Full-year organic net sales growth against guidance of 6.5% to 7.0%.
  • Full-year adjusted net earnings per diluted share against guidance of $14.80 to $14.90.
  • The expected modestly positive pricing impact and slightly favorable foreign-exchange impact.
  • The company's expected solid performance in Q4 and good momentum heading into 2027.
  • Further costs associated with structural optimization and other special charges, goodwill and other impairments, medical device regulations, recall-related matters, and regulatory and legal matters.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 3,271 million at September 30, 2026, compared with $ 4,011 million at December 31, 2025.
  • Long-term debt, excluding current maturities, was $ 14,176 million at September 30, 2026, compared with $ 14,859 million at December 31, 2025.
  • Accounts receivable, net, were $ 3,693 million at September 30, 2026, compared with $ 4,039 million at December 31, 2025.
  • Inventories were $ 5,747 million at September 30, 2026, compared with $ 5,310 million at December 31, 2025.
  • Net cash provided by operating activities was $ 3,303 million for the nine months 2026, compared with $ 2,901 million for the nine months 2025.
  • Acquisitions, net of cash acquired, were $ (481) million for the nine months 2026, compared with $ (4,950) million for the nine months 2025.
  • Net cash used in investing activities was $ (1,011) million for the nine months 2026, compared with $ (4,561) million for the nine months 2025.
  • Net cash used in financing activities was $ (2,998) million for the nine months 2026, compared with net cash provided by financing activities of $ 1,206 million for the nine months 2025.
  • Change in cash and cash equivalents was $ (740) million for the nine months 2026, compared with $ (396) million for the nine months 2025.

Analysis

Stryker recorded $ 6,520 million of third-quarter net sales, up 7.7%, with organic net sales also up 7.7%. The release attributes consolidated organic growth primarily to increased unit volume. MedSurg and Neurotechnology was the principal growth contributor, with sales of $ 3,664 million up 9.2% and organic sales growth of 9.1%. Orthopaedics sales were $ 2,856 million, up 5.7%, with 5.9% organic growth. United States sales increased 8.3% to $ 4,950 million, while International sales increased 5.7% to $ 1,570 million.

Reported profitability was affected by charges, despite gross-margin improvement. Gross profit margin was 65.2%, compared with 63.6%, while reported operating income margin declined to 15.9% from 18.7%. Operating income decreased 8.9% to $ 1,034 million, net earnings decreased 12.3% to $ 753 million, and diluted EPS decreased 11.7% to $ 1.96. Goodwill and other impairments were $ 293 million, compared with $ 73 million. The reconciliation also identifies $ 153 million of structural optimization and other special charges in adjusted operating income and $ 293 million of goodwill and other impairments.

Underlying adjusted results improved. Adjusted gross profit margin was 65.4%, compared with 65.0%, and adjusted operating income margin increased 60 bps to 26.2% from 25.6%. Adjusted net earnings increased 10.1% to $ 1,357 million and adjusted diluted EPS increased 10.3% to $ 3.52. Product-level performance was uneven: Endoscopy grew 13.9%, Ortho Tech grew 15.8%, and Vascular grew 8.0%, while Hips declined (1.0) % and Spinal Implants declined (43.9) %.

For the first nine months, net cash provided by operating activities increased to $ 3,303 million from $ 2,901 million. The company used $ (605) million for purchases of property, plant and equipment, paid $ (1,012) million of dividends, and repurchased $ (1,000) million of common stock. Cash and cash equivalents were $ 3,271 million and long-term debt, excluding current maturities, was $ 14,176 million at September 30, 2026. The Board approved an additional $3.0 billion for the existing share repurchase program in October 2026.

Management updated full-year 2026 guidance to organic net sales growth of 6.5% to 7.0% and adjusted net earnings per diluted share of $14.80 to $14.90. The company said its sales guidance includes a modestly positive pricing impact and expects foreign exchange to have a slightly favorable effect on sales and adjusted EPS if rates remain near current levels. Management explicitly said the quarter fell short of expectations, making fourth-quarter delivery against the updated ranges and the stated expectation for solid Q4 performance central to the outlook.

Management, verbatim

We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter. While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.

Kevin A. Lobo, Chair and CEO

Not in the filing

stated, not guessed
  • Previous-release outlook and prior-guidance comparisons were not provided.
  • Quarterly operating cash flow was not reported.
  • Free cash flow was not reported.
  • Full-year 2026 GAAP revenue, GAAP EPS, gross margin, operating expenses and tax-rate guidance were not reported.
  • Third-quarter dividend declared per share was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Stryker released its Q3 2026 operating results via a Form 8‑K, detailing sales, margins, EPS, share repurchases, and revised full‑year outlook.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Stryker (NYSE:SYK) filed an 8‑K reporting Q3 2026 results and updated full‑year guidance to 6.5‑7.0% organic sales growth and $14.80‑$14.90 adjusted EPS.

Expected impact

likely modest downside as investors price in slower organic growth and lower EPS expectations

Evidence & confidence

the guidance revision signals slower top‑line growth and lower earnings than prior expectations, which may pressure the stock in the near term.

Market effects

medical device sector may see broader scrutiny of growth forecasts

U.S. healthcare stocks could experience slight pressure

limited to investors tracking large‑cap med‑tech earnings

Counterpoint

if the market overreacts to the modest guidance, a bounce could occur on the back of strong underlying unit volume growth

Key entities

  • Kevin A. Lobo

    Chair and CEO of Stryker, quoted on performance and outlook

Every SYK earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.